SAR440340

Phase 3Small molecule

Sanofi

SAR440340 is one of 108 small molecule programs targeting Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Chronic Rhinosinusitis With Nasal PolypsEnrolling by invitation

AsthmaActive, not recruiting

HepatitisPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Chronic Rhinosinusitis With Nasal PolypsPhase 3

Enrolling by invitation

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

SAR440340

Sanofi

Phase 3

1 2

Veramyst

GSK

Preclinical

46 3

Xolair

Roche

Preclinical

25 4

Singulair

AstraZeneca

Preclinical

17 5

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 6

Cinqair

Teva

Preclinical

13 7

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 8

Asmanex

Novartis

Preclinical

5 9

Celexa

AbbVie

Preclinical

1 10

Spiriva

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma1 trial

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Completed· Sanofi logo

Sanofi·Phase 2·NCT03387852·296 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Completed· Sanofi logo

Sanofi·Phase 2·NCT03546907·343 enrolled

Chronic Rhinosinusitis With Nasal Polyps1 trial

A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Participated in Either EFC18418 or EFC18419 Clinical Studies

Enrolling by invitation· Sanofi logo

Sanofi·Phase 3·NCT07424144·380 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SAR440340. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR440340 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR440340. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

SAR440340

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma1 trial

Chronic Obstructive Pulmonary Disease1 trial

Chronic Rhinosinusitis With Nasal Polyps1 trial

References

Drug Info

Quick Facts

Related News